DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083 September 20, 2017 • 5:30 AM EDT
DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer September 18, 2017 • 8:00 AM EDT
DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme September 11, 2017 • 4:00 AM EDT
DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017 September 6, 2017 • 1:59 PM EDT
DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM July 24, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM July 18, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman July 11, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable June 29, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM June 22, 2017 • 8:30 AM EDT
DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference June 16, 2017 • 8:30 AM EDT